Celgene will discontinue phase III ORIGIN® trial in previously untreated elderly patients with B-cell chronic lymphocytic leukemia

Celgene Corporation has announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID® (lenalidomide) in the open-label, phase III ORIGIN® trial, which enrolled 450 patients in over 100 sites in 26 countries. An imbalance was observed in the number of deaths in patients treated with lenalidomide versus patients treated with chlorambucil. Read more here.